GlassScriptPhysician profile
Shaun Michael Gifford
NPI 1558576918
$69,708.25
in general payments reported to CMS, 2019-2025
25 companies · $5,022 in 2025
The $5,022 reported for 2025 was more than what 84% of Vascular Surgery providers received nationally (typical 2025 total: $927).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,325 · 2020: $669 · 2021: $1,375 · 2022: $14K · 2023: $23K · 2024: $24K · 2025: $5,022.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $17K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $15K · Food and Beverage: $13K · Travel and Lodging: $4,790 · Debt Forgiveness: $1,824.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $16,800.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $15,400.00 |
| Food and Beverage | $13,107.38 |
| Travel and Lodging | $4,790.08 |
| Debt Forgiveness | $1,823.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Silk Road Medical, INC. | $42,128.88 | 2019-2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Shockwave Medical, INC | $12,697.33 | 2020-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| W. L. Gore & Associates, INC. | $4,619.62 | 2019-2025 | Gore Excluder Thoracoabdominal Branch Endoprosthesis, Gore Tag Thoracic Branch Endoprosthesis, Excluder Conformable Aaa Endoprosthesis With Active Control |
| Penumbra, INC. | $2,631.30 | 2024-2025 | Indigo System, Penumbra System |
| Medtronic, INC. | $1,825.35 | 2021-2025 | Endurant Iis, Heli-Fx Endoanchor System, In.Pact Admiral |
| Angiodynamics, INC. | $1,823.51 | 2023 | Auryon Atherectomy Catheter 0.9 Mm Otw |
| Boston Scientific Corporation | $1,568.48 | 2023-2025 | General - Vascular Intervention, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Cook Medical LLC | $775.48 | 2019-2025 | Zenith Spiral-Z, Zenith Alpha, Cook |
| Medtronic Vascular, INC. | $460.95 | 2019-2020 | |
| Endologix LLC | $254.58 | 2025 | Alto Abdominal Stent Graft System |
| Bolton Medical INC | $216.31 | 2019-2024 | Treo Abdominal Stent-Graft System, Tr Band, Relay Thoracic Stent-Graft With Plus Delivery System |
| Terumo Medical Corporation | $165.00 | 2022-2024 | Glidesheath Slender, Tr Band |
| Reflow Medical INC | $143.84 | 2025 | |
| Cardiovascular Systems INC. | $87.88 | 2020 | |
| Cvrx, INC. | $85.62 | 2024 | Barostim Neo System |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $58.33 | 2023 | Jeti |
| Lemaitre Vascular, INC. | $28.18 | 2021-2023 | Albograft Polyester Vascular Graft |
| Philips North America LLC | $22.00 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.04 | 2019 | |
| Janssen Pharmaceuticals, INC | $18.66 | 2020 | |
| Ekos Corporation | $18.43 | 2019 | |
| Convatec INC. | $17.47 | 2024 | |
| Ethicon US, LLC | $15.51 | 2021 | |
| Bard Peripheral Vascular, INC. | $15.18 | 2019 | |
| Covidien LP | $11.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shaun Gifford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.